Based on the Genmab AS stock forecast from 3 analysts, the average analyst target price for Genmab AS is USD 43.67 over the next 12 months. Genmab AS’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Genmab AS is Neutral, which is based on 2 positive signals and 2 negative signals. At the last closing, Genmab AS’s stock price was USD 19.21. Genmab AS’s stock price has changed by -1.89% over the past week, -10.53% over the past month and -30.90% over the last year.
Analyst Ratings
Target Price Action
Rating Action
Analyst
Rating
Price
Date
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Add to Watchlists
loading..
Download Confirmation
Premium customers can only download records visible on the current page view, while Platinum customers can download the first 1000 records.
Paid-only feature
CSV downloads are only available for paying customers.
Thank you for Sharing your Stock Targets for GMAB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
